Clin2
NCT07537972Possibly a fitNot yet recruiting

Denosumab with Immunotherapy for Liver Cancer Spread to Bones

Hepatocellular Carcinoma (HCC)Bone Metastases

Treatments studied

Part of Cancer, Digestive system clinical trials.

This study tests whether adding denosumab (a bone-strengthening medication) to immunotherapy helps patients with liver cancer that has spread to their bones. Denosumab may help reduce bone pain and prevent fractures while the immunotherapy fights the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
50 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You have hepatocellular carcinoma (liver cancer) confirmed by imaging or biopsy
  • Cancer has spread to your bones, confirmed by imaging
  • You are able to perform light activities (ECOG score 0–1)
  • Your liver function is good enough for treatment (Child-Pugh A or stable B7)
  • You have not received PD-1 inhibitors or similar immunotherapies before
  • You are willing to have a dental assessment and avoid unnecessary dental work during the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07537946Not yet recruiting· Phase 3
Immunotherapy Plus Targeted Drug for Advanced Liver Cancer

This trial tests a combination of two drugs (sintilimab, an immunotherapy, and lenvatinib, a targeted therapy) followed by local treatments to try to cure advanced liver cancer that has spread to a few other parts of the body. The goal is to shrink the cancer enough that surgery or radiation can remove it completely.

Wuhan, Hubei
NCT07034391Recruiting· Phase 2
PD-1 inhibitor with denosumab and chemo for advanced lung cancer

This trial tests a combination of an immunotherapy drug (PD-1 inhibitor), a bone-strengthening drug (denosumab), and chemotherapy for people with advanced or spread non-squamous non-small cell lung cancer that does not have certain genetic changes. The goal is to see if this combination helps shrink tumors and control the disease.

Shenyang, Liaoning
NCT07028268Recruiting· Phase 2
Testing a new drug for bone metastases from solid tumors

This trial tests a new drug called SHR-2017 for people with solid tumors that have spread to the bones. The study aims to see if the drug can help manage pain and other effects of bone metastases.

Guangzhou, Guangdong
NCT03958565Recruiting
Study how targeted drugs affect bone tumors in lung cancer

This trial studies how tyrosine kinase inhibitor (TKI) medicines work against non-small cell lung cancer that has spread to the bone. It’s for people with specific “actionable” gene changes, to see how well these treatments reduce or change bone metastases.

Aurora, Colorado
NCT07271771Recruiting· Phase 4
Denosumab for muscle and insulin in diabetes

This study tests whether denosumab, a medication that strengthens bones, can also improve muscle strength and insulin sensitivity in postmenopausal women with type 2 diabetes who take metformin.

Aarhus
NCT07555210Recruiting
Bone Density Changes During Cancer Immunotherapy

This study tracks how a type of cancer treatment called anti-PD-1 immunotherapy affects bone strength over time. Researchers want to understand whether this treatment causes bone density loss and help develop ways to protect bones during cancer care.

Nashville, Tennessee

Hear when a new Hepatocellular Carcinoma (HCC) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.